ProSurg Could Capitalize on WLF Decision To Market InjecTx For BPH
This article was originally published in The Gray Sheet
Executive Summary
Prosurg's future marketing strategy for the InjecTx transurethral injection system depends heavily on FDA's interpretation of the recent federal court decision in Washington Legal Foundation v. Henney.